Indications
Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub-syndrome of Acute Radiation Syndrome (H-ARS). Imreplys should be used in accordance with official radiological/nuclear emergency recommendations.
Composition
- Active substance
- sargramostim
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Imreplys
- Active substance
- sargramostim
- ATC code
- L03AA09
- Therapeutic area
- Acute Radiation Syndrome
- Marketing authorisation holder
- Partner Therapeutics Limited